Supporting the Next Generation of Breast Cancer Therapies

Breast cancer treatment has evolved significantly over the last decade, driven by the adoption of targeted therapies that improve treatment outcomes while helping preserve patients' quality of life. Among these innovations, Ribociclib has established itself as a leading CDK4/6 inhibitor for patients with HR-positive, HER2-negative breast cancer, both in advanced and metastatic settings and, more recently, in certain early-stage high-risk patients.

At Suanfarma, we help pharmaceutical companies advance their oncology pipelines through the supply of high-quality Ribociclib Succinate API, backed by strong technical expertise, regulatory support, and scalable manufacturing capabilities.

Understanding Ribociclib: Mechanism of Action

Ribociclib is a selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), key proteins involved in regulating cell-cycle progression and cellular proliferation. By inhibiting these kinases, Ribociclib prevents phosphorylation of the retinoblastoma (Rb) protein, effectively arresting tumour cells in the G1 phase and slowing cancer cell growth.

This targeted mechanism has demonstrated substantial clinical benefit when used in combination with endocrine therapies, including aromatase inhibitors and fulvestrant, making it a cornerstone treatment option in HR-positive, HER2-negative breast cancer.

As an oral therapy, Ribociclib provides an effective treatment approach that helps delay disease progression while supporting long-term patient management.

Why Ribociclib Continues to Gain Importance in Oncology

Breast cancer remains one of the most prevalent cancers worldwide, driving continued demand for innovative treatment solutions.

Thanks to its proven efficacy and established clinical profile, Ribociclib has become one of the most widely recognized CDK4/6 inhibitors in oncology. Ongoing clinical developments continue to reinforce its importance across multiple stages of breast cancer treatment.

For pharmaceutical companies, this creates a growing opportunity to develop differentiated products within a well-established therapeutic area.

Suanfarma Ribociclib Succinate API

Suanfarma offers Ribociclib Succinate (CAS 1374639-75-4) in Polymorphic Form A, with particle size tailored to customer-specific requirements.

To support development and registration activities, the product is backed by an Open Part DMF, facilitating customer assessment, regulatory submissions, and development programs.

Our Ribociclib Succinate API benefits from extensive process optimization and analytical development, ensuring high levels of quality, consistency, and regulatory readiness.

Key Product Features

• Purity >98%
• Total impurities around 0.1%
• Confirmed Polymorphic Form A
• Stable at room temperature
• Customizable particle size
• Open Part DMF available
• Samples from validation batches available for customer evaluation and qualification activities
• GMP manufacturing capacity up to 500 kg/year
• Manufactured in OEB 4 facilities with advanced containment systems
• Competitive pricing and scalable supply capabilities

Built for Development and Commercial Supply

Successful oncology programs require more than a high-quality API. They require a partner capable of supporting development, registration, scale-up and commercialization.

Development & Regulatory Support

Suanfarma provides a comprehensive regulatory package designed to facilitate customer development and registration activities worldwide:

• Open Part DMF available
• Confirmed Polymorphic Form A
• Extensive impurity characterization
• Compliance with general regulatory expectations
• Dedicated technical and regulatory support throughout the project lifecycle

In addition, our manufacturing process demonstrates strong impurity control, supporting demanding quality requirements and facilitating development activities across multiple regulatory environments.

Manufacturing & Supply Reliability

Our manufacturing and supply capabilities are designed to support both clinical and commercial requirements:

• Robust and reproducible manufacturing processes
• Consistent batch-to-batch quality
• Scalable supply for development and commercialization
• GMP production capacity up to 500 kg/year
• Responsive technical support and project management
• Long-term partnership approach

Why Partner with Suanfarma for Ribociclib API?

Developing oncology therapies requires a partner capable of supporting projects from early development through commercial launch.

Suanfarma differentiates its Ribociclib offering through:

• Differentiated Nitrosamine Control

Advanced process control strategies designed to achieve low nitrosamine levels, providing flexibility as regulatory expectations continue to evolve.

• Convenient Storage Conditions

Storage at 20-25°C under controlled conditions, without refrigeration requirements, simplifying handling, warehousing, and transportation throughout the supply chain.

The Suanfarma Advantage:

• Strong expertise in oncology APIs
• Proven technical and regulatory know-how
• Global commercial network
• Commitment to quality, innovation, and patient access
• Reliable supply backed by rigorous quality standards

Advancing Oncology Development Together

As demand for innovative breast cancer therapies continues to grow, Ribociclib remains a strategic molecule for pharmaceutical companies focused on expanding their oncology portfolios.

With a high-quality, regulatory-ready API, scalable manufacturing capabilities, and dedicated technical support, Suanfarma is ready to help partners accelerate development and secure reliable long-term supply.

Suanfarma APIs. European manufacturing. Global confidence.

Contact our team to learn more about our Ribociclib Succinate API and oncology capabilities.